Clinical Trial Update: Trial of Memantine for Cognitive Impairment in Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

A completed clinical trial evaluating memantine for cognitive impairment in multiple sclerosis (Phase 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognition Disorders
• Multiple Sclerosis

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Multiple Sclerosis, Cognition Disorders | Phase 2, Phase 3 | Status: COMPLETED